sutantatug envedotin + pembrolizumab

CRB-701 + Keytruda is an investigational combination therapy consisting of sutantatug envedotin (CRB-701), a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, and pembrolizumab (Keytruda), a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor. Sutantatug envedotin is designed with a site-specific, cleavable linker and a homogeneous drug-to-antibody ratio (DAR) of 2, delivering a monomethyl auristatin E (MMAE) cytotoxic payload directly to Nectin-4-expressing tumor cells. Pembrolizumab acts as an immune checkpoint inhibitor, preventing PD-1 from interacting with its ligands (PD-L1 and PD-L2) to restore T-cell-mediated anti-tumor immune responses. Developed by Corbus Pharmaceuticals (licensed from CSPC Pharmaceutical Group), this combination is being evaluated in a Phase 1/2 clinical trial (NCT06265727) for the treatment of advanced or metastatic Nectin-4-expressing solid tumors, with priority focus on first-line head and neck squamous cell carcinoma (HNSCC), specifically oropharyngeal squamous cell carcinoma (OPSCC), and cervical cancer.